These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10073371)

  • 1. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
    Neumann PJ
    J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
    Meltzer D
    J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics in the managed care era.
    Loebel AD; Botts SR; Feldman BI
    Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems.
    Hamann J; Leucht S; Kissling W
    Pharmacopsychiatry; 2003 Jan; 36(1):18-26. PubMed ID: 12649770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulary decisions and health economics.
    Glazer WM
    J Clin Psychiatry; 1998; 59 Suppl 19():23-9. PubMed ID: 9847049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
    Revicki DA
    J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual health outcomes and treatment costs for schizophrenia populations.
    Mauskopf JA; David K; Grainger DL; Gibson PJ
    J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of treating mental illness from a managed care perspective.
    Docherty JP
    J Clin Psychiatry; 1999; 60 Suppl 3():49-52; discussion 53. PubMed ID: 10073378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome in schizophrenia: beyond symptom reduction.
    Meltzer HY
    J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomics of antipsychotic drug therapy.
    Hargreaves WA; Shumway M
    J Clin Psychiatry; 1996; 57 Suppl 9():66-76. PubMed ID: 8823354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?
    Hansen K; Lançon C; Toumi M
    Eur J Health Econ; 2006 Mar; 7(1):19-29. PubMed ID: 16528579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of schizophrenia: let's talk dollars and sense.
    Buckley PF
    Am J Manag Care; 1998 Mar; 4(3):369-83. PubMed ID: 10178499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving mental health treatments through comparative effectiveness research.
    Wang PS; Ulbricht CM; Schoenbaum M
    Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Looking beyond the formulary budget in cost-benefit analysis.
    Cohen LJ
    Am J Manag Care; 1997 Feb; 3 Suppl():S11-7. PubMed ID: 10180337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.